trending Market Intelligence /marketintelligence/en/news-insights/trending/fC8TCRNZueqntG_pkPunkw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Biolase prices $4.2M common stock offering, $4M preferred shares placement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Biolase prices $4.2M common stock offering, $4M preferred shares placement

Biolase Inc. priced its underwritten public offering of 7,820,000 common shares and its concurrent private placement of 69,565 unregistered convertible preferred shares.

The Irvine, Calif.-based company is selling common shares at 57.5 cents per share. Biolase also granted underwriters a 30-day over-allotment option to buy up to an additional 1,173,000 common shares.

Meanwhile, investors affiliated with Jack W. Schuler and Oracle Investment Management Inc. agreed to purchase the preferred shares at $57.50 apiece in the concurrent placement. Each preferred share is automatically convertible into 100 common shares at a conversion price of 57.5 cents per share, subject to anti-dilution adjustments.

Biolase expects net proceeds of about $4.2 million from the common stock offering, or about $4.8 million if the underwriters exercise their option in full. The company anticipates about $4 million in gross proceeds from the private placement.

Net proceeds will be used for working capital — including product development, launch and scale-ups — and general corporate purposes.

The public offering and private placement are expected to close on Oct. 29.

The Benchmark Co. LLC and Dougherty & Co. LLC are acting underwriters for the common stock offering.

Biolase, a medical device company, develops laser systems for use in dentistry and medicine.